191 related articles for article (PubMed ID: 8631797)
21. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins.
Jeschke M; Wels W; Dengler W; Imber R; Stöcklin E; Groner B
Int J Cancer; 1995 Mar; 60(5):730-9. PubMed ID: 7860149
[TBL] [Abstract][Full Text] [Related]
22. Structural and functional aspects of the multiplicity of Neu differentiation factors.
Wen D; Suggs SV; Karunagaran D; Liu N; Cupples RL; Luo Y; Janssen AM; Ben-Baruch N; Trollinger DB; Jacobsen VL
Mol Cell Biol; 1994 Mar; 14(3):1909-19. PubMed ID: 7509448
[TBL] [Abstract][Full Text] [Related]
23. Bivalence of EGF-like ligands drives the ErbB signaling network.
Tzahar E; Pinkas-Kramarski R; Moyer JD; Klapper LN; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin BJ; Sela M; Andrews GC; Yarden Y
EMBO J; 1997 Aug; 16(16):4938-50. PubMed ID: 9305636
[TBL] [Abstract][Full Text] [Related]
24. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors.
Bacus SS; Gudkov AV; Zelnick CR; Chin D; Stern R; Stancovski I; Peles E; Ben-Baruch N; Farbstein H; Lupu R
Cancer Res; 1993 Nov; 53(21):5251-61. PubMed ID: 8106145
[TBL] [Abstract][Full Text] [Related]
25. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Ethier SP; Kokeny KE; Ridings JW; Dilts CA
Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
[TBL] [Abstract][Full Text] [Related]
26. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2.
Zhang K; Sun J; Liu N; Wen D; Chang D; Thomason A; Yoshinaga SK
J Biol Chem; 1996 Feb; 271(7):3884-90. PubMed ID: 8632008
[TBL] [Abstract][Full Text] [Related]
27. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch C; Weiss FU; Niederfellner G; Jallal B; Issing W; Ullrich A
EMBO J; 1995 Sep; 14(17):4267-75. PubMed ID: 7556068
[TBL] [Abstract][Full Text] [Related]
28. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.
Graus-Porta D; Beerli RR; Daly JM; Hynes NE
EMBO J; 1997 Apr; 16(7):1647-55. PubMed ID: 9130710
[TBL] [Abstract][Full Text] [Related]
29. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
Sliwkowski MX; Schaefer G; Akita RW; Lofgren JA; Fitzpatrick VD; Nuijens A; Fendly BM; Cerione RA; Vandlen RL; Carraway KL
J Biol Chem; 1994 May; 269(20):14661-5. PubMed ID: 7514177
[TBL] [Abstract][Full Text] [Related]
30. Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation.
Pinkas-Kramarski R; Eilam R; Alroy I; Levkowitz G; Lonai P; Yarden Y
Oncogene; 1997 Dec; 15(23):2803-15. PubMed ID: 9419971
[TBL] [Abstract][Full Text] [Related]
31. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
32. The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4.
Riese DJ; Kim ED; Elenius K; Buckley S; Klagsbrun M; Plowman GD; Stern DF
J Biol Chem; 1996 Aug; 271(33):20047-52. PubMed ID: 8702723
[TBL] [Abstract][Full Text] [Related]
33. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
Daly JM; Olayioye MA; Wong AM; Neve R; Lane HA; Maurer FG; Hynes NE
Oncogene; 1999 Jun; 18(23):3440-51. PubMed ID: 10376522
[TBL] [Abstract][Full Text] [Related]
34. Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3.
Horan T; Wen J; Arakawa T; Liu N; Brankow D; Hu S; Ratzkin B; Philo JS
J Biol Chem; 1995 Oct; 270(41):24604-8. PubMed ID: 7592681
[TBL] [Abstract][Full Text] [Related]
35. Activity-dependent regulation of Neu differentiation factor/neuregulin expression in rat brain.
Eilam R; Pinkas-Kramarski R; Ratzkin BJ; Segal M; Yarden Y
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1888-93. PubMed ID: 9465112
[TBL] [Abstract][Full Text] [Related]
36. Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins.
Levkowitz G; Klapper LN; Tzahar E; Freywald A; Sela M; Yarden Y
Oncogene; 1996 Mar; 12(5):1117-25. PubMed ID: 8649804
[TBL] [Abstract][Full Text] [Related]
37. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
38. NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells.
Marte BM; Graus-Porta D; Jeschke M; Fabbro D; Hynes NE; Taverna D
Oncogene; 1995 Jan; 10(1):167-75. PubMed ID: 7824269
[TBL] [Abstract][Full Text] [Related]
39. HER4 receptor activation and phosphorylation of Shc proteins by recombinant heregulin-Fc fusion proteins.
Culouscou JM; Carlton GW; Aruffo A
J Biol Chem; 1995 May; 270(21):12857-63. PubMed ID: 7759543
[TBL] [Abstract][Full Text] [Related]
40. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner.
Olayioye MA; Graus-Porta D; Beerli RR; Rohrer J; Gay B; Hynes NE
Mol Cell Biol; 1998 Sep; 18(9):5042-51. PubMed ID: 9710588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
